Group 1 - The core viewpoint of the article is that Jinkai Biotechnology (301509.SZ) has a pipeline of clinical projects focused on various disease treatment areas, including oncology and immunology [1] - The company emphasizes its commitment to strictly adhere to information disclosure regulations when providing updates on project information [1] Group 2 - The clinical projects in the company's pipeline are related to multiple disease treatment fields, indicating a diversified approach to research and development [1] - The company is actively engaging with investors through an interactive platform, showcasing transparency in its operations [1]